(NASDAQ: ANTX) An2 Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.78%.
An2 Therapeutics's earnings in 2026 is -$36,276,000.On average, 4 Wall Street analysts forecast ANTX's earnings for 2026 to be -$34,449,411, with the lowest ANTX earnings forecast at -$34,392,806, and the highest ANTX earnings forecast at -$34,075,822. On average, 4 Wall Street analysts forecast ANTX's earnings for 2027 to be -$30,792,769, with the lowest ANTX earnings forecast at -$31,804,101, and the highest ANTX earnings forecast at -$29,321,056.
In 2028, ANTX is forecast to generate -$31,562,589 in earnings, with the lowest earnings forecast at -$31,804,101 and the highest earnings forecast at -$30,905,978.